Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatment with standard of care will be presented at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025). The conference is being held July 17 - 20, 2025 at the Fontainebleau Miami Beach Hotel in Miami Beach, Florida.

DPNP is a highly prevalent but often overlooked debilitating chronic complication of diabetes. DPNP can result in burning pain, numbness, and other symptoms in the hands, feet, legs, and arms. There are approximately 9 million patients in the U.S. who are suffering with DPNP. Previous research shows that DPNP affects an estimated 30% of patients with type 1 diabetes and 50% of patients with type 2 diabetes.